A number of other research analysts have also weighed in on the stock. Raymond James cut their target price on shares of Avanos Medical from $57.00 to $48.00 and set an outperform rating for the company in a research report on Wednesday, August 7th. Zacks Investment Research lowered shares of Avanos Medical from a hold rating to a sell rating in a research report on Monday, May 6th. Stifel Nicolaus set a $45.00 target price on shares of Avanos Medical and gave the stock a buy rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley set a $47.00 price objective on shares of Avanos Medical and gave the company a sell rating in a research report on Wednesday, May 8th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Avanos Medical presently has an average rating of Hold and an average target price of $57.50.
Avanos Medical stock opened at $32.75 on Wednesday. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of 39.94 and a beta of 1.46. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.06 and a quick ratio of 2.35. Avanos Medical has a fifty-two week low of $32.60 and a fifty-two week high of $72.96. The firm has a fifty day moving average price of $39.73 and a two-hundred day moving average price of $42.69.
In related news, CEO Joseph Fralin Woody acquired 3,500 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was acquired at an average price of $39.95 per share, with a total value of $139,825.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.57% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of AVNS. RGM Capital LLC increased its stake in Avanos Medical by 1,659.3% in the second quarter. RGM Capital LLC now owns 751,523 shares of the company’s stock valued at $32,774,000 after acquiring an additional 708,806 shares during the period. Victory Capital Management Inc. increased its stake in Avanos Medical by 31.3% in the first quarter. Victory Capital Management Inc. now owns 2,196,725 shares of the company’s stock valued at $93,756,000 after acquiring an additional 523,550 shares during the period. Rice Hall James & Associates LLC bought a new stake in Avanos Medical in the first quarter valued at about $16,219,000. Champlain Investment Partners LLC increased its stake in Avanos Medical by 14.5% in the first quarter. Champlain Investment Partners LLC now owns 2,401,987 shares of the company’s stock valued at $102,517,000 after acquiring an additional 304,015 shares during the period. Finally, Paradice Investment Management LLC increased its stake in Avanos Medical by 17.8% in the second quarter. Paradice Investment Management LLC now owns 1,991,583 shares of the company’s stock valued at $86,853,000 after acquiring an additional 301,082 shares during the period. 92.12% of the stock is currently owned by institutional investors and hedge funds.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Recommended Story: Outstanding Shares
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.